Metal complexes
AssigneeSmithKline Beecham Corporation
InventorsJohn G. Gleason, Juan I. Luengo
Life of this patent
Estimating the term…
Abstract
The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.
Claims53
A method for agonizing dimeric cell-surface receptors in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a zinc chelated dimeric cell-surface receptor ligand.
A method for agonizing dimeric cell-surface receptors in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of an organic molecule having a molecular weight from about 100 to about 850, containing of from 1 to 4 zinc binding motifs and provided that each zinc binding motif forms at least two coordinate bonds to a zinc ion.
A method for identifying agonists of dimeric cell-surface receptors which comprises contacting the receptor with dimeric cell-surface receptor ligand candidates in the presence of a zinc ion source, and selecting ligand candidates which bind to the receptor.
A process for the preparation of a zinc chelated dimeric cell-surface receptor ligand which comprises reacting one or more receptor binding moieties and a zinc ion source followed by optional isolation of the zinc chelated dimeric cell-surface receptor ligand.
A zinc chelated cell-surface receptor ligand.
An isolated dimeric cell-surface receptor binding moiety of a zinc chelated cell-surface receptor ligand.
A dimeric cell-surface receptor binding moiety.
Dependencies are inferred from the claim text.